1月9日，迪哲医药涨5.2%，截至发稿，报66.75元/股，成交2.41亿元，换手率0.81%，总市值307.84亿 元。 资料显示，迪哲(江苏)医药股份有限公司位于江苏省无锡市新吴区和风路26号汇融商务广场C栋404、 405、416室,中国(上海)自由贸易试验区亮景路199、245号4幢，成立日期2017年10月27日，上市日期 2021年12月10日，公司主营业务涉及创新药物的研发和产业化,高度重视员工的创新研发能力。主营业 务收入构成为：销售药品100.00%。 从基金十大重仓股角度 数据显示，同泰基金旗下1只基金重仓迪哲医药。同泰大健康主题混合A（011002）三季度持有股数3.76 万股，占基金净值比例为5.41%，位居第五大重仓股。根据测算，今日浮盈赚取约12.42万元。 同泰大健康主题混合A（011002）成立日期2021年4月8日，最新规模1375.12万。今年以来收益7.74%， 同类排名577/8827；近一年收益25.89%，同类排名4600/8084；成立以来亏损50.98%。 同泰大健康主题混合A（011002）基金经理为马毅、麦健沛。 截至发稿，马毅累计任职时间11年299天，现 ...

Core Viewpoint - The China Securities Investment Fund Industry Association has revised the "Performance Assessment Management Guidelines for Fund Management Companies (Draft for Comments)," which stipulates that fund managers of actively managed equity funds with poor performance for three consecutive years may face a salary reduction of 30% [1] Group 1: Performance Assessment Guidelines - The new guidelines establish a tiered performance salary adjustment mechanism, where if the performance of actively managed equity products falls below the benchmark by more than 10 percentage points over three years and the fund's profit margin is negative, the performance salary should decrease significantly, with a reduction of no less than 30% [1] - If the performance is below the benchmark by more than 10 percentage points but the fund's profit margin is positive, the performance salary should still decrease [1] Group 2: Fund Performance Issues - The "personal system" public fund company Tongtai Fund has several actively managed equity funds facing issues such as small scale and performance divergence, with multiple funds underperforming their benchmarks over the past three years [1] - Data shows that among Tongtai Fund's actively managed equity funds, half of the products have seen a decline in net value over the last three years, with nine products underperforming their benchmarks [2] Group 3: Specific Fund Performance - Tongtai Kaitai Mixed A has seen a net value decline of over 28% in the last three years, underperforming its benchmark by nearly 41 percentage points [3] - Tongtai Huaying Mixed A has experienced a net value drop of over 13%, underperforming its benchmark by nearly 27 percentage points [3] - The fund manager Wang Xiu has been in charge for just under two years, and the previous manager Yang Zhe has moved to another fund company, which may indicate a larger responsibility for the poor performance [3] Group 4: Fund Management Scale and Ranking - Tongtai Fund, established in October 2018, is the 14th "personal system" public fund company in China, with a total management scale of 4.728 billion yuan as of the end of the third quarter of 2025, ranking 143rd among public fund institutions [5] - The company manages 22 products, with five stock funds totaling 458 million yuan and nine mixed funds totaling 1.043 billion yuan, accounting for over 30% of its total management scale [5] - Several funds, including Tongtai Huaying Mixed and Tongtai Huizhe Mixed, have scales below 50 million yuan, approaching the liquidation threshold [5]

Group 1 - The article provides a ranking of open-end funds based on their net asset value growth as of October 23, 2025, highlighting the top 10 and bottom 10 funds [2][4][6] - The top-performing funds include 泰信现代服务业混合, 泰信发展主题混合, and various 招商中证煤炭等权指数 funds, with 泰信现代服务业混合 showing a net value of 1.7280 [2][6] - The bottom-performing funds include 中航优选领航混合发起C and 中航优选领航混合发起A, with 中航优选领航混合发起C showing a net value of 1.7109 [4][6] Group 2 - The overall market performance indicates a slight increase in the Shanghai Composite Index, with a trading volume of 1.66 trillion and a stock gain-loss ratio of 2994:2302 [6] - Leading sectors include oil and chemical fibers, both showing gains of over 2%, while sectors like communication equipment and construction materials faced declines [6] - The article notes that 泰信现代服务业混合 has experienced rapid net value growth, indicating strong performance in the current market environment [6]

Group 1 - Yifang Biotechnology's stock increased by 5.25%, reaching a price of 28.25 CNY per share, with a trading volume of 204 million CNY and a turnover rate of 1.75%, resulting in a total market capitalization of 16.338 billion CNY [1] - Yifang Biotechnology (Shanghai) Co., Ltd. was established on January 11, 2013, and went public on July 25, 2022. The company focuses on the research, production, and sales of innovative drugs, with its main revenue source being technology licensing and cooperation, accounting for 100% of its revenue [1] Group 2 - According to data, the Tongtai Health Theme Mixed A Fund (011002) holds a significant position in Yifang Biotechnology, with 37,200 shares, representing 5.42% of the fund's net value, making it the fourth-largest holding [2] - The Tongtai Health Theme Mixed A Fund was established on April 8, 2021, with a latest scale of 6.1823 million CNY. Year-to-date returns are 29.83%, ranking 2955 out of 8161 in its category, while the one-year return is 22.6%, ranking 4191 out of 8021 [2] - The fund manager, Ma Yi, has a tenure of 11 years and 214 days, managing assets totaling 6.063 billion CNY, with the best return during his tenure being 40.95% and the worst being -0.63% [2] - Co-manager Mai Jianpei has a tenure of 158 days, managing assets of 161 million CNY, with the best return during his tenure being 22.24% and the worst being -2.2% [2]

Group 1 - The core viewpoint of the article is that Tongtai Fund predicts an unprecedented bull market in the A-share market, with the Shanghai Composite Index potentially reaching 10,000 points, indicating a possible increase of about 194% from the current level of around 3,600 points [2][4] - The DDM model presented by Tongtai Fund supports the prediction, with two models indicating significant upside potential for the A-share market. The zero-growth model suggests a 35% upside, while the stable growth model indicates a 194% upside based on a dividend growth rate of 1% [4] - The performance of Tongtai Fund's products has been relatively strong this year, with several funds showing positive returns, such as Tongtai Vision A with a year-to-date return of 54.10% [5][22] Group 2 - Tongtai Fund's investment strategy involves frequent changes in the top holdings of its funds, with the Tongtai Vision Mixed Fund showing a tendency to replace its top ten holdings regularly [10][22] - Despite the strong performance of some funds, there are concerns about the overall investment strategy, as the Tongtai Vision Mixed Fund has experienced significant losses in previous years, indicating a low success rate in stock selection [14][15] - The article highlights that many funds under Tongtai Fund have concentrated positions in specific sectors, which may lead to increased volatility and risk [22]